^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IBI-310 (ipilimumab biosimilar)

i
Other names: IBI-310, IBI310, IBI 310
Associations
Company:
Innovent Biologics
Drug class:
CTLA4 inhibitor
Associations
7d
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
P2, N=4, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Terminated; After careful consideration, our company has decided to revise the overall development strategy for IBI310 and discontinue further registration research for this project. Consequently, the ongoing screening process will be terminated, and this decisi
Trial termination • Combination therapy • Mismatch repair • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
2ms
Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=97, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Apr 2023 --> Jun 2024
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
3ms
New P2 trial
|
Tyvyt (sintilimab) • Lenvima (lenvatinib) • IBI-310 (ipilimumab biosimilar)
8ms
Phase classification • Enrollment change • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
11ms
P1 data • Journal • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
11ms
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy (clinicaltrials.gov)
P2, N=205, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
over1year
Enrollment open • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
over1year
New P1 trial • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
almost2years
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment (clinicaltrials.gov)
P2, N=40, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Ariely (adebrelimab) • IBI-310 (ipilimumab biosimilar)
2years
Trial primary completion date • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
almost3years
Clinical • New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tyvyt (sintilimab) • Sulanda (surufatinib) • IBI-310 (ipilimumab biosimilar)
almost4years
Clinical • Enrollment closed • Enrollment change • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
4years
IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient(dMMR)/Microsatellite Instability High (MSI-H)Locally-advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
P2, N=68, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2020 --> Aug 2020
Clinical • Enrollment open • Trial initiation date • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
over4years
[VIRTUAL] IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study. (ASCO 2020)
IBI310 monotherapy or in combination with sintilimab were well-tolerated without unanticipated AEs in pts with advanced melanoma. The data preliminarily demonstrate an antitumor activity of the combination therapy in previously treated advanced melanoma (acral and NCSD melanomas). Research Funding: Innovent Biologics, Inc.
Clinical • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)